POLE ultra-mutated endometrial cancer and immunotherapy

SF73

In addition to ultra-mutated endometrial cancer due to microsatellite instability (MSI), it seems if the tumor has the POLE exonuclease domain mutations then they would make good candidates for immunotherapy. It seems 10% of the endometrial cancer (both types) gets this mutation. If you have this mutation in your genomic profiling and are currently experiencing a recurrence maybe discuss the possibility of immunotherapy with your doctor. 

A few papers:

https://www.ncbi.nlm.nih.gov/pubmed/27362548

https://www.sciencedirect.com/science/article/pii/S0959804917311462

https://www.ncbi.nlm.nih.gov/pubmed/28427513

christine8822

New research also shows benefit for recurrent MSI-H patients

Thanks for links. I follow the research and interested to see this report from SGO meeting. It was looking at cost effectiveness of pembrolizumab (Keytruda) for recurrent endometrial cancer., but it included survival rates that are promising if you are MSI-H.  Included is this interesting graph:  Of 4400 included patients, 800 were classified as MSI-H. The 2-year overall survival rates were 20% with PLD, 40% with bevacizumab, 50% with pembrolizumab among MSI-L patients, and 64% with pembrolizumab among MSI-H patients. Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.

whole link is here:   https://www.cancertherapyadvisor.com/sgo-2018/endometrial-cancer-pembrolizumab-cost-effective-recurrent-treatment/article/754124/